SCHEMBL4553003

SCHEMBL4553003

CC1=C(CC(=O)O)c2cc(NS(=O)(=O)c3sc4ccc(Cl)cc4c3C)ccc2C1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.71
PFKFB3 Q16875 9/20 0.58
PFKFB4 Q16877 8/20 0.58
NPSR1 Q6W5P4 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CMA1 P23946 3/20 0.56
HTR1A P08908 2/20 0.50
HTR1D P28221 2/20 0.50
HTR1B P28222 2/20 0.50
HTR2A P28223 2/20 0.50
HTR7 P34969 2/20 0.50
DRD2 P14416 1/20 0.50
HTR2C P28335 1/20 0.50
HTR1E P28566 1/20 0.50
HTR1F P30939 1/20 0.50
ADRA1B P35368 1/20 0.50
DRD3 P35462 1/20 0.50
HTR2B P41595 1/20 0.50
HTR4 Q13639 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14538814 0.91 HTR6 (0.58) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL2907465 0.88 HTR6 (0.74) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL2905817 0.85 HTR6 (0.75) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL2907927 0.83 HTR6 (1.00) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL733290 0.77 NPSR1 (0.65) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL11662750 0.77 ABCB11 (0.38) HTR6
SCHEMBL12204617 0.76 NPSR1 (0.90) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL5621758 0.75 PFKFB3 (0.80) PFKFB3PFKFB4NPSR1L3MBTL1CMA1
SCHEMBL2905740 0.75 NPSR1 (0.62) HTR6PFKFB3PFKFB4NPSR1L3MBTL1
SCHEMBL9996951 0.74 PFKFB3 (0.84) HTR6PFKFB3PFKFB4NPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US claimed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP claimed
US-8217041-B2 Indene derivatives, their preparation and use as medicaments Laboratories del Sr. Esteve, S.A. (ES) 2012-07-10 US disclosed
US-8217041-B2 Indene derivatives, their preparation and use as medicaments Laboratories del Sr. Esteve, S.A. (ES) 2012-07-10 US disclosed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US disclosed
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US disclosed
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US disclosed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264457-A1 Combination of at least two 5HT6-Ligands HTR6, HTR3B, HTR4 HTR6 1/4885PFKFB3 2797/4885PFKFB4 2725/4885
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS HTR6, HTR5A, HTR1A HTR6 1/4885PFKFB3 2130/4885PFKFB4 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.